Patients
5.9 % of adults
Obesity (adults), Japan, 2024 (WHO).
Compare every country on the Public Health Dashboard
Updated
Reviewed by Vidhi Upadhyay
Japan Intragastric Balloon Market Industry Trends and Forecast to 2034: Segmented by (Type, Filling, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$28.5 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $15.2 Mn | — | — |
| 2025 (base) | $16.9 Mn | +$1.8 Mn | — |
| 2026 (forecast) | $18.9 Mn | +$2.0 Mn | +11.6% |
| 2027 (forecast) | $21.1 Mn | +$2.2 Mn | +24.5% |
| 2028 (forecast) | $23.5 Mn | +$2.4 Mn | +39% |
| 2029 (forecast) | $26.3 Mn | +$2.7 Mn | +55.1% |
| 2030 (forecast) | $29.3 Mn | +$3.0 Mn | +73.1% |
| 2031 (forecast) | $32.7 Mn | +$3.4 Mn | +93.2% |
| 2032 (forecast) | $36.5 Mn | +$3.8 Mn | +115.6% |
| 2033 (forecast) | $40.8 Mn | +$4.2 Mn | +140.6% |
| 2034 (forecast) | $45.5 Mn | +$4.7 Mn | +168.5% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $16.9 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $45.5 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 11.6% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Type, filling and end user (see all) |
| Key players | Allurion Technologies, Apollo Endosurgery, Spatz Medical, Obalon Therapeutics, Helioscopie (see all) |
| Regulator in Japan | PMDASource: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Intragastric balloons are soft balloons placed in the stomach for a few months to help people eat less and lose weight without surgery.
Key segments of the intragastric Balloon market include type (Single Balloon, Dual Balloon and Swallowable Balloon) and filling (Saline-Filled and Gas-Filled).
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the intragastric Balloon market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the intragastric Balloon market, especially in fast-growing emerging economies.
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the intragastric Balloon market. Long-term safety data and lifestyle support are still needed for many patients.
The intragastric Balloon market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medical devices are notified, certified or approved depending on their risk; the Pharmaceuticals and Medical Devices Agency (PMDA) reviews higher-risk devices for approval by the Ministry of Health, Labour and Welfare.[1] Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices).[2] Obesity (adults): 5.9% of adults in 2024, the latest WHO figure for Japan.[3]
[1] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
[2] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
[3] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 20 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how intragastric Balloon products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Japan.
What doctors and scientists are doing in Intragastric Balloon right now, from free public sources.
5.9 % of adults
Obesity (adults), Japan, 2024 (WHO).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 20 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 19 Nov 2026.
[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.
[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.
From our blog
Japan
Japan
Japan
Japan
Japan
Japan
Pharmaceuticals · Japan
Pharmaceuticals · Japan
Healthcare Services · Japan
Digital Health · Japan
Pharmaceuticals · Japan
Pharmaceuticals · Japan